Alignment Healthcare, Inc. (NASDAQ:ALHC) Receives Consensus Rating of “Moderate Buy” from Analysts

Alignment Healthcare, Inc. (NASDAQ:ALHC) has been given an average recommendation of “Moderate Buy” by the thirteen research firms that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have given a buy rating and one has issued a strong buy rating on the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $23.95.

ALHC has been the topic of a number of research reports. Wall Street Zen raised Alignment Healthcare from a “hold” rating to a “buy” rating in a research note on Saturday, February 7th. Robert W. Baird set a $28.00 target price on shares of Alignment Healthcare in a report on Friday, January 30th. Barclays boosted their price target on shares of Alignment Healthcare from $13.00 to $18.00 and gave the stock an “equal weight” rating in a research report on Friday, October 31st. TD Cowen increased their price objective on shares of Alignment Healthcare from $18.50 to $25.00 and gave the company a “buy” rating in a research report on Friday, January 16th. Finally, KeyCorp restated an “overweight” rating and issued a $28.00 target price on shares of Alignment Healthcare in a report on Thursday, January 22nd.

Key Stories Impacting Alignment Healthcare

Here are the key news stories impacting Alignment Healthcare this week:

• Positive Sentiment: Q4 results beat near‑term expectations — Alignment reported ($0.05) EPS vs. consensus (~$0.15 loss) and revenue of ~$1.01B, up ~44% year‑over‑year, showing strong top‑line growth. Alignment Healthcare Reports Fourth Quarter and Full‑Year 2025 Results
• Positive Sentiment: Company highlighted record revenue and membership gains, supporting continued Medicare Advantage enrollment momentum that underpins revenue visibility. Alignment Healthcare Inc (ALHC) Q4 2025 Earnings Call Highlights
• Neutral Sentiment: Analyst writeups and metric comparisons confirmed the beat but note persistent negative margins and ROE; these pieces provide context on profitability trends and model updates. Zacks — Key Metrics Versus Estimates
• Neutral Sentiment: Conference call / press release and filings are available for details on membership trends, medical cost assumptions and guidance drivers for 2026. Quarterly Report / Press Release PDF
• Neutral Sentiment: Reported short‑interest data in public feeds appears erroneous (zeros/NaN); no reliable short‑interest signal from those entries. Market data / profile
• Negative Sentiment: Forward guidance disappointed: Q1 revenue guidance (~$1.2B) below the ~ $1.3B street estimate and FY 2026 revenue guidance of $5.1B–$5.2B sits at or slightly under consensus — investors reacted to the softer top‑line outlook. Guidance details in Earnings Release
• Negative Sentiment: Profitability remains a concern — the company still shows a small negative net margin and negative return on equity, and management did not provide explicit EPS guidance for 2026, leaving investors uncertain on near‑term earnings conversion. Zacks — Q4 Loss, Beats Revenue Estimates

Alignment Healthcare Stock Down 5.9%

Shares of ALHC stock opened at $19.22 on Friday. The company’s fifty day simple moving average is $20.99 and its two-hundred day simple moving average is $18.51. Alignment Healthcare has a 52 week low of $11.63 and a 52 week high of $23.87. The stock has a market cap of $3.85 billion, a P/E ratio of -1,920.08, a PEG ratio of 5.20 and a beta of 1.16. The company has a quick ratio of 1.61, a current ratio of 1.61 and a debt-to-equity ratio of 1.99.

Alignment Healthcare (NASDAQ:ALHC) last issued its earnings results on Thursday, February 26th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.10. The firm had revenue of $1.01 billion for the quarter, compared to analysts’ expectations of $1 billion. Alignment Healthcare had a negative return on equity of 0.53% and a negative net margin of 0.02%.The business’s revenue was up 44.4% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.16) earnings per share. Analysts predict that Alignment Healthcare will post -0.69 EPS for the current fiscal year.

Insider Buying and Selling

In other Alignment Healthcare news, CEO John E. Kao sold 605,648 shares of the company’s stock in a transaction that occurred on Monday, December 29th. The stock was sold at an average price of $18.74, for a total transaction of $11,349,843.52. Following the sale, the chief executive officer directly owned 2,234,294 shares in the company, valued at $41,870,669.56. This represents a 21.33% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, President Dawn Christine Maroney sold 282,070 shares of Alignment Healthcare stock in a transaction that occurred on Monday, December 29th. The stock was sold at an average price of $18.74, for a total value of $5,285,991.80. Following the completion of the transaction, the president owned 1,385,167 shares of the company’s stock, valued at approximately $25,958,029.58. This trade represents a 16.92% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 2,125,938 shares of company stock worth $41,799,570. Corporate insiders own 7.00% of the company’s stock.

Institutional Investors Weigh In On Alignment Healthcare

Several hedge funds and other institutional investors have recently made changes to their positions in the company. T. Rowe Price Investment Management Inc. grew its stake in Alignment Healthcare by 0.6% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 12,643,784 shares of the company’s stock valued at $249,715,000 after purchasing an additional 79,268 shares during the last quarter. Invesco Ltd. increased its holdings in Alignment Healthcare by 38.9% in the 4th quarter. Invesco Ltd. now owns 6,202,592 shares of the company’s stock worth $122,501,000 after buying an additional 1,735,962 shares during the period. Mercer Global Advisors Inc. ADV raised its holdings in shares of Alignment Healthcare by 6.9% during the fourth quarter. Mercer Global Advisors Inc. ADV now owns 15,452 shares of the company’s stock worth $305,000 after purchasing an additional 996 shares during the last quarter. Mackenzie Financial Corp boosted its holdings in Alignment Healthcare by 25.6% in the fourth quarter. Mackenzie Financial Corp now owns 46,917 shares of the company’s stock valued at $901,000 after purchasing an additional 9,552 shares during the last quarter. Finally, nVerses Capital LLC purchased a new position in shares of Alignment Healthcare during the 4th quarter valued at about $396,000. Hedge funds and other institutional investors own 86.19% of the company’s stock.

Alignment Healthcare Company Profile

Alignment Healthcare, Inc (NASDAQ: ALHC) is a health care company specializing in value-based care for Medicare Advantage beneficiaries. The company leverages an integrated care model that combines in-home clinical services, telehealth capabilities and digital health tools to manage chronic conditions, improve outcomes and enhance patient experience.

At the core of Alignment Healthcare’s approach is a proprietary technology platform that aggregates real-time clinical and claims data to support preventive care, risk stratification and personalized care plans.